Details of the Drug Combinations

General Information of This Drug (ID: DMNH3PG)

Drug Name
Etoposide   DMNH3PG
Synonyms
etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Adult acute monocytic leukemia N.A. Approved [1]
Adult kidney Wilms tumor N.A. Approved [1]
Beckwith-Wiedemann syndrome N.A. Approved [1]
Childhood kidney Wilms tumor N.A. Approved [1]
Hamartoma N.A. Approved [1]
Kidney neoplasm N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Small-cell lung cancer 2C25.Y Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Testicular cancer 2C80 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Neuroblastoma 2D11.2 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

453 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
(-)-englerin A + Etoposide DCXM1PJ (-)-englerin A Ewing sarcoma (Cell Line: TC-71) [5]
ABT-263 + Etoposide DCFUXQB ABT-263 Ewing sarcoma (Cell Line: TC-71) [6]
Cantharidin + Etoposide DCYGQUS Cantharidin Ewing sarcoma (Cell Line: TC-71) [5]
Etoposide + PD-0325901 DCFW7M0 PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + PD-0325901 DCXEMK1 PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + PD-0325901 DCAQBON PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + PD-0325901 DCNUD3H PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + PD-0325901 DCAU6Z7 PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + PD-0325901 DCOF1EO PD-0325901 Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + PD-0325901 DC84ILQ PD-0325901 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + PD-0325901 DC2TKG0 PD-0325901 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + PD-0325901 DCUBUR7 PD-0325901 Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + PD-0325901 DC4NRYF PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + PD-0325901 DC7CP0F PD-0325901 Germ cell tumour (Cell Line: PA1) [5]
Etoposide + PD-0325901 DC2ZWZ3 PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + PD-0325901 DCBXS1W PD-0325901 Malignant melanoma (Cell Line: A375) [5]
Etoposide + PD-0325901 DC8HEMC PD-0325901 Malignant melanoma (Cell Line: HT144) [5]
Etoposide + PD-0325901 DC72OJJ PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + PD-0325901 DCF6WNH PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + PD-0325901 DCTCPIB PD-0325901 Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + PD-0325901 DCWM0RI PD-0325901 Mesothelioma (Cell Line: MSTO) [5]
Etoposide + PD-0325901 DCSTDWN PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [5]
Etoposide + PD-0325901 DCQUX7Z PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + PD-0325901 DCNE4SX PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + PD-0325901 DCYVZVV PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + PD-0325901 DC3X626 PD-0325901 Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + Lapatinib DCJKUYN Lapatinib Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + Lapatinib DC93UNY Lapatinib Adenocarcinoma (Cell Line: A427) [5]
Etoposide + Lapatinib DC51YQZ Lapatinib Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + Lapatinib DCJ2IA8 Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + Lapatinib DC34QBY Lapatinib Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + Lapatinib DCNDOQJ Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + Lapatinib DCM03AU Lapatinib Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + Lapatinib DCJMOCK Lapatinib Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + Lapatinib DCOR98A Lapatinib Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + Lapatinib DC7015V Lapatinib Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + Lapatinib DCREIRF Lapatinib Malignant melanoma (Cell Line: HT144) [5]
Etoposide + Lapatinib DCRV7CW Lapatinib Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + Lapatinib DCWOZPY Lapatinib Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + Lapatinib DCX5LG3 Lapatinib Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + Lapatinib DCIOBEW Lapatinib Mesothelioma (Cell Line: MSTO) [5]
Etoposide + Lapatinib DCI7RNJ Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Lapatinib DCXGS8O Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + Lapatinib DCE4HR5 Lapatinib Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + Lapatinib DCH65TQ Lapatinib Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + MK-1775 DCFB4LH MK-1775 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + MK-1775 DC3GGQD MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + MK-1775 DC12MK4 MK-1775 Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + MK-1775 DCG7OO3 MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + MK-1775 DCN9QZH MK-1775 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + MK-1775 DCDT878 MK-1775 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + MK-1775 DC35IR0 MK-1775 Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + MK-1775 DC4TR78 MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + MK-1775 DCV6OVC MK-1775 Malignant melanoma (Cell Line: A375) [5]
Etoposide + MK-1775 DCKLQP1 MK-1775 Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + MK-1775 DCW9MLK MK-1775 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + MK-1775 DC0RP68 MK-1775 Mesothelioma (Cell Line: MSTO) [5]
Etoposide + MK-1775 DCT7T04 MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + MK-1775 DCUDZX1 MK-1775 Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + PMID28460551-Compound-2 DCHP7WM PMID28460551-Compound-2 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + PMID28460551-Compound-2 DC8780N PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + PMID28460551-Compound-2 DCOFA9W PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + PMID28460551-Compound-2 DCC93ZO PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH23) [5]
Etoposide + PMID28460551-Compound-2 DCT3CO6 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + PMID28460551-Compound-2 DCB0VNF PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + PMID28460551-Compound-2 DCP7OIZ PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + PMID28460551-Compound-2 DCS702W PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + PMID28460551-Compound-2 DCTS7WU PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + PMID28460551-Compound-2 DCUJHPK PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [5]
Etoposide + PMID28460551-Compound-2 DCXPD4U PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + PMID28460551-Compound-2 DCNVHSK PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + PMID28460551-Compound-2 DCC42VD PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + PMID28460551-Compound-2 DCTHLGF PMID28460551-Compound-2 Malignant melanoma (Cell Line: HT144) [5]
Etoposide + PMID28460551-Compound-2 DCY96JH PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + PMID28460551-Compound-2 DC2JOGP PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + PMID28460551-Compound-2 DC4YLZB PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + PMID28460551-Compound-2 DCNIL0O PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [5]
Etoposide + PMID28460551-Compound-2 DC0D9HT PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [5]
Etoposide + PMID28460551-Compound-2 DCQBNIU PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + PMID28460551-Compound-2 DCG9KR8 PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + PMID28460551-Compound-2 DC99B7M PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + PMID28460551-Compound-2 DCCFWGO PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + Panobinostat DCBTLGX Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Etoposide + RTB101 DCLOGBF RTB101 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + RTB101 DC5URWJ RTB101 Adenocarcinoma (Cell Line: A427) [5]
Etoposide + RTB101 DCXJ1DI RTB101 Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + RTB101 DCYJTNR RTB101 Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + RTB101 DCRBCPZ RTB101 Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + RTB101 DCRVXQS RTB101 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + RTB101 DCM0SFR RTB101 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + RTB101 DC1WX4U RTB101 Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + RTB101 DCS84HW RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + RTB101 DC31F8J RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + RTB101 DCPU5CQ RTB101 Malignant melanoma (Cell Line: A375) [5]
Etoposide + RTB101 DCIPAF8 RTB101 Malignant melanoma (Cell Line: HT144) [5]
Etoposide + RTB101 DCEDP0E RTB101 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + RTB101 DC0OM8K RTB101 Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + RTB101 DCK46GG RTB101 Mesothelioma (Cell Line: MSTO) [5]
Etoposide + RTB101 DCUIA73 RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + RTB101 DCZ19AK RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + RTB101 DC7LUNV RTB101 Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + RTB101 DC904B0 RTB101 Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + SCH-900776 DC897PH SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + SCH-900776 DCPJKPX SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [5]
Etoposide + SCH-900776 DCH0785 SCH-900776 Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + SCH-900776 DCIGISI SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + SCH-900776 DCEKAFX SCH-900776 Adenocarcinoma (Cell Line: NCIH23) [5]
Etoposide + SCH-900776 DC6DWMH SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + SCH-900776 DCHTPZ9 SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + SCH-900776 DC7Z4V3 SCH-900776 Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + SCH-900776 DC5UOTV SCH-900776 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + SCH-900776 DC8TUFA SCH-900776 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + SCH-900776 DCZHJXN SCH-900776 Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + SCH-900776 DCW57HO SCH-900776 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + SCH-900776 DCY2PYG SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + SCH-900776 DCVUKR5 SCH-900776 Malignant melanoma (Cell Line: HT144) [5]
Etoposide + SCH-900776 DCPPP23 SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + SCH-900776 DCPCXD8 SCH-900776 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + SCH-900776 DCZZUXM SCH-900776 Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + SCH-900776 DCIEBDC SCH-900776 Mesothelioma (Cell Line: MSTO) [5]
Etoposide + SCH-900776 DCJV1CM SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + SCH-900776 DC9H87F SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + SCH-900776 DCNMLOI SCH-900776 Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + SCH-900776 DCEL9DT SCH-900776 Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + GDC-0084 DC4S7JQ GDC-0084 Ewing sarcoma (Cell Line: TC-71) [5]
Etoposide + SNX-2112 DC3N1UQ SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + SNX-2112 DCOCZ91 SNX-2112 Adenocarcinoma (Cell Line: A427) [5]
Etoposide + SNX-2112 DCMUJYF SNX-2112 Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + SNX-2112 DCI5S6P SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + SNX-2112 DCV4I6T SNX-2112 Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + SNX-2112 DC2M15B SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + SNX-2112 DCD2GWJ SNX-2112 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + SNX-2112 DCDRA37 SNX-2112 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + SNX-2112 DC3IADM SNX-2112 Adenocarcinoma (Cell Line: SW-620) [5]
Etoposide + SNX-2112 DCPW6OT SNX-2112 Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + SNX-2112 DCLA0BK SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + SNX-2112 DCV845B SNX-2112 Malignant melanoma (Cell Line: A375) [5]
Etoposide + SNX-2112 DCPKW2H SNX-2112 Malignant melanoma (Cell Line: HT144) [5]
Etoposide + SNX-2112 DC73LKV SNX-2112 Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + SNX-2112 DCRZX19 SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + SNX-2112 DCVJZ30 SNX-2112 Mesothelioma (Cell Line: MSTO) [5]
Etoposide + SNX-2112 DCIC1SN SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [5]
Etoposide + SNX-2112 DCIBKK3 SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + SNX-2112 DCAZAFO SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + SNX-2112 DCTYPNI SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + SNX-2112 DCB4KDT SNX-2112 Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + AT7519 DC53VV8 AT7519 Ewing sarcoma (Cell Line: TC-71) [5]
Etoposide + SCH 727965 DCAOOS0 SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + SCH 727965 DC4WLKD SCH 727965 Adenocarcinoma (Cell Line: A427) [5]
Etoposide + SCH 727965 DCFVFM4 SCH 727965 Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + SCH 727965 DCOR5HJ SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + SCH 727965 DCP9KO3 SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + SCH 727965 DC0X1PD SCH 727965 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + SCH 727965 DC5DB8D SCH 727965 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + SCH 727965 DCPHKDC SCH 727965 Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + SCH 727965 DC9SCOV SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + SCH 727965 DC2T2PJ SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + SCH 727965 DCLQVXA SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + SCH 727965 DC2MDCN SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + SCH 727965 DCVW22R SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + SCH 727965 DCCIXZ5 SCH 727965 Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + SCH 727965 DCAP27V SCH 727965 Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + Erlotinib DC3YHKV Erlotinib Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + Erlotinib DCI6C05 Erlotinib Adenocarcinoma (Cell Line: A427) [5]
Etoposide + Erlotinib DCSVFBW Erlotinib Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + Erlotinib DCUC0UZ Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + Erlotinib DC30ZB7 Erlotinib Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + Erlotinib DCB30RD Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + Erlotinib DC63PYD Erlotinib Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + Erlotinib DCVHS5C Erlotinib Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + Erlotinib DCG6CWP Erlotinib Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + Erlotinib DCTCG3W Erlotinib Adenocarcinoma (Cell Line: SW-620) [5]
Etoposide + Erlotinib DC2YI0K Erlotinib Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + Erlotinib DCRBX9C Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + Erlotinib DCQR8F5 Erlotinib Malignant melanoma (Cell Line: A375) [5]
Etoposide + Erlotinib DC5KBP3 Erlotinib Malignant melanoma (Cell Line: HT144) [5]
Etoposide + Erlotinib DC5ECPF Erlotinib Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + Erlotinib DC86MOO Erlotinib Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + Erlotinib DCCIMT7 Erlotinib Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + Erlotinib DCWW83N Erlotinib Mesothelioma (Cell Line: MSTO) [5]
Etoposide + Erlotinib DC59P1V Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Erlotinib DCMZ603 Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + Erlotinib DCF8TUO Erlotinib Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + Erlotinib DC1O6ES Erlotinib Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + THAPSIGARGIN DCDCQUD THAPSIGARGIN Ewing sarcoma (Cell Line: TC-71) [5]
Etoposide + AEE-788 DCJII5O AEE-788 Ewing sarcoma (Cell Line: TC-71) [5]
Etoposide + MK-5108 DCYI0SI MK-5108 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + MK-5108 DC73F9R MK-5108 Adenocarcinoma (Cell Line: A427) [5]
Etoposide + MK-5108 DCICOME MK-5108 Adenocarcinoma (Cell Line: NCIH23) [5]
Etoposide + MK-5108 DCDLKIR MK-5108 Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + MK-5108 DCBWLK5 MK-5108 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + MK-5108 DCO31Q7 MK-5108 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + MK-5108 DCBDCE7 MK-5108 Adenocarcinoma (Cell Line: SW-620) [5]
Etoposide + MK-5108 DC8PBXB MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + MK-5108 DCGFQOX MK-5108 Germ cell tumour (Cell Line: PA1) [5]
Etoposide + MK-5108 DCKOU9F MK-5108 Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + MK-5108 DCSPQFF MK-5108 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + MK-5108 DCFSVO3 MK-5108 Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + MK-5108 DCYVDYU MK-5108 Mesothelioma (Cell Line: MSTO) [5]
Etoposide + MK-5108 DCARDKE MK-5108 Non small cell carcinoma (Cell Line: SKMES1) [5]
Etoposide + MK-5108 DCNKB04 MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + MK-5108 DC1R8Q3 MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + Ridaforolimus DCUX6G9 Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + Ridaforolimus DC4Y9Z8 Ridaforolimus Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + Ridaforolimus DCF0E3Z Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + Ridaforolimus DCB8OFC Ridaforolimus Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + Ridaforolimus DCX1YQ3 Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + Ridaforolimus DCEHM8Z Ridaforolimus Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + Ridaforolimus DC8JKKI Ridaforolimus Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + Ridaforolimus DC06FJZ Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + Ridaforolimus DCCKZKO Ridaforolimus Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + Ridaforolimus DCU5033 Ridaforolimus Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + Ridaforolimus DC1XQKW Ridaforolimus Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + Ridaforolimus DCGDTSF Ridaforolimus Mesothelioma (Cell Line: MSTO) [5]
Etoposide + Ridaforolimus DCKZD5R Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Ridaforolimus DC6I0CI Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + Ridaforolimus DCI1W22 Ridaforolimus Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + MK-4827 DCGF74C MK-4827 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + MK-4827 DC0U5JR MK-4827 Adenocarcinoma (Cell Line: A427) [5]
Etoposide + MK-4827 DCS3W2X MK-4827 Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + MK-4827 DC3XMI8 MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + MK-4827 DC69KFQ MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + MK-4827 DCJQT6O MK-4827 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + MK-4827 DC9JCGH MK-4827 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + MK-4827 DCE2H04 MK-4827 Adenocarcinoma (Cell Line: SW-620) [5]
Etoposide + MK-4827 DCLBMJY MK-4827 Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + MK-4827 DC4N4B2 MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + MK-4827 DCV0LOA MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + MK-4827 DCO8PVZ MK-4827 Malignant melanoma (Cell Line: A375) [5]
Etoposide + MK-4827 DCZ9IL7 MK-4827 Malignant melanoma (Cell Line: HT144) [5]
Etoposide + MK-4827 DCX9256 MK-4827 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + MK-4827 DCEXRDJ MK-4827 Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + MK-4827 DCHCVDJ MK-4827 Mesothelioma (Cell Line: MSTO) [5]
Etoposide + MK-4827 DCFDAH9 MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [5]
Etoposide + MK-4827 DCXB48K MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + MK-4827 DC5HQEH MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + MK-4827 DCIUIZG MK-4827 Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + MK-4827 DCEXNVT MK-4827 Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + Idarubicin DCHXGNQ Idarubicin Adenocarcinoma (Cell Line: NCIH23) [5]
Etoposide + Idarubicin DCLOVGJ Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + Idarubicin DC06LL9 Idarubicin Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + Idarubicin DCG40UT Idarubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + Idarubicin DCBDV3I Idarubicin Glioblastoma? (Cell Line: T98G) [5]
Etoposide + Idarubicin DCVTL32 Idarubicin Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + Idarubicin DCNCD8M Idarubicin Mesothelioma (Cell Line: MSTO) [5]
Etoposide + Idarubicin DCMQP4X Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Bortezomib DC8ZHT9 Bortezomib Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + Bortezomib DCXB46N Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + Bortezomib DCS0R4D Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + Bortezomib DCHSVVQ Bortezomib Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + Bortezomib DC2L8YX Bortezomib Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + Bortezomib DC6DFEM Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + Bortezomib DCOJNE9 Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + Bortezomib DCSOGXX Bortezomib Malignant melanoma (Cell Line: A375) [5]
Etoposide + Bortezomib DC1QAKG Bortezomib Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + Bortezomib DCQ7V0Y Bortezomib Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + Bortezomib DCDF7P0 Bortezomib Mesothelioma (Cell Line: MSTO) [5]
Etoposide + Bortezomib DCQI2L4 Bortezomib Non small cell carcinoma (Cell Line: SKMES1) [5]
Etoposide + Bortezomib DC0AN1M Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Bortezomib DC89GPI Bortezomib Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + GSK525762 DCKHRTU GSK525762 Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + GSK525762 DC7SDN6 GSK525762 Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + GSK525762 DCHSM0H GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Tetrahydrouridine DCQCB6G Tetrahydrouridine Hodgkin lymphoma (Cell Line: U-HO1) [5]
Etoposide + Sorafenib DCN48PK Sorafenib Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + Sorafenib DC1HOVO Sorafenib Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + Sorafenib DCSUHMC Sorafenib Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + Sorafenib DCCXLM1 Sorafenib Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + Sorafenib DCPUR7D Sorafenib Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + Sorafenib DCZLJAL Sorafenib Adenocarcinoma (Cell Line: SW-620) [5]
Etoposide + Sorafenib DCSZU8N Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + Sorafenib DC54RP4 Sorafenib Malignant melanoma (Cell Line: A375) [5]
Etoposide + Sorafenib DCQ1D34 Sorafenib Malignant melanoma (Cell Line: HT144) [5]
Etoposide + Sorafenib DCORPO3 Sorafenib Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + Sorafenib DCI6Q3O Sorafenib Mesothelioma (Cell Line: MSTO) [5]
Etoposide + Sorafenib DCV1LMT Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [5]
Etoposide + Sorafenib DCU2C8U Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Sorafenib DC9HFU6 Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + MK-2206 DC8EQSU MK-2206 Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + MK-2206 DC6JGMK MK-2206 Adenocarcinoma (Cell Line: A427) [5]
Etoposide + MK-2206 DCUKA8H MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + MK-2206 DCAN8JX MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + MK-2206 DCALRA9 MK-2206 Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + MK-2206 DC6ZPPM MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + MK-2206 DCIKPGM MK-2206 Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + MK-2206 DCRSR2C MK-2206 Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + MK-2206 DCN44PF MK-2206 Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + MK-2206 DC4C133 MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Etoposide + MK-2206 DCLLK3A MK-2206 Germ cell tumour (Cell Line: PA1) [5]
Etoposide + MK-2206 DCSZ8OK MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Etoposide + MK-2206 DC375FU MK-2206 Malignant melanoma (Cell Line: HT144) [5]
Etoposide + MK-2206 DCLZB9R MK-2206 Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + MK-2206 DC5CLGR MK-2206 Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + MK-2206 DCR5UGT MK-2206 Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + MK-2206 DCA0PBQ MK-2206 Mesothelioma (Cell Line: MSTO) [5]
Etoposide + MK-2206 DCRF3Q1 MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [5]
Etoposide + MK-2206 DC9G65A MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + MK-2206 DCQK074 MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + MK-2206 DC1N0ZM MK-2206 Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + MK-2206 DCY5EJN MK-2206 Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + Romidepsin DCZJSVE Romidepsin Ewing sarcoma (Cell Line: TC-71) [5]
Etoposide + Doxorubicin DCDUJDF Doxorubicin Ewing sarcoma (Cell Line: TC-71) [5]
Etoposide + Ibrutinib DCRC0LT Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [5]
Etoposide + Dasatinib DC7OLL9 Dasatinib Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + Dasatinib DCEBIP9 Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Etoposide + Dasatinib DCRC013 Dasatinib Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + Dasatinib DCVYUCE Dasatinib Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + Dasatinib DCB4BJC Dasatinib Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + Dasatinib DC97VMI Dasatinib Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + Dasatinib DCS8SNS Dasatinib Germ cell tumour (Cell Line: PA1) [5]
Etoposide + Dasatinib DC40SRU Dasatinib Malignant melanoma (Cell Line: A375) [5]
Etoposide + Dasatinib DC8TMBL Dasatinib Mesothelioma (Cell Line: MSTO) [5]
Etoposide + Dasatinib DC2E59W Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Cytarabine DCTGD8J Cytarabine Ewing sarcoma (Cell Line: TC-71) [5]
Etoposide + PD-0325901 DC0JL94 PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [7]
Etoposide + PD-0325901 DCP2BVK PD-0325901 Breast carcinoma (Cell Line: ZR751) [7]
Etoposide + PD-0325901 DCYBN4X PD-0325901 Breast carcinoma (Cell Line: KPL1) [7]
Etoposide + PD-0325901 DCIBB8E PD-0325901 Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + PD-0325901 DCVOVFB PD-0325901 Carcinoma (Cell Line: OV90) [7]
Etoposide + PD-0325901 DCNU553 PD-0325901 Carcinoma (Cell Line: EFM192B) [7]
Etoposide + PD-0325901 DCF1W5I PD-0325901 Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + PD-0325901 DCXCY8S PD-0325901 Colon carcinoma (Cell Line: RKO) [7]
Etoposide + PD-0325901 DC9XTLY PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + PD-0325901 DCANEJ9 PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + Lapatinib DCJUJ4V Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [7]
Etoposide + Lapatinib DCWLF6D Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [7]
Etoposide + Lapatinib DCNL6VW Lapatinib Breast carcinoma (Cell Line: ZR751) [7]
Etoposide + Lapatinib DC2JMJ4 Lapatinib Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + Lapatinib DCHC1VS Lapatinib Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + Lapatinib DCCXPRB Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [7]
Etoposide + Lapatinib DCSKTVU Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + MK-1775 DCTEUUY MK-1775 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [7]
Etoposide + MK-1775 DCK7Y1K MK-1775 Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + MK-1775 DC4LU4S MK-1775 Colon carcinoma (Cell Line: RKO) [7]
Etoposide + PMID28460551-Compound-2 DC3QO8T PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [7]
Etoposide + PMID28460551-Compound-2 DCK6UYC PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [7]
Etoposide + PMID28460551-Compound-2 DCVZIYM PMID28460551-Compound-2 Breast carcinoma (Cell Line: ZR751) [7]
Etoposide + PMID28460551-Compound-2 DC7VKRD PMID28460551-Compound-2 Breast carcinoma (Cell Line: KPL1) [7]
Etoposide + PMID28460551-Compound-2 DC2LV0Z PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + PMID28460551-Compound-2 DCTAFPA PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [7]
Etoposide + PMID28460551-Compound-2 DCL5TV9 PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [7]
Etoposide + PMID28460551-Compound-2 DCUPZSV PMID28460551-Compound-2 Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + PMID28460551-Compound-2 DCHU06E PMID28460551-Compound-2 Colon adenocarcinoma (Cell Line: LOVO) [7]
Etoposide + PMID28460551-Compound-2 DCU9IJY PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [7]
Etoposide + PMID28460551-Compound-2 DCNWTJ8 PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + PMID28460551-Compound-2 DCH2VPH PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + RTB101 DCN1XD8 RTB101 Breast carcinoma (Cell Line: ZR751) [7]
Etoposide + RTB101 DCE2347 RTB101 Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + RTB101 DC5MYFX RTB101 Carcinoma (Cell Line: OV90) [7]
Etoposide + RTB101 DCXW99M RTB101 Carcinoma (Cell Line: EFM192B) [7]
Etoposide + RTB101 DC9L6XG RTB101 Colon carcinoma (Cell Line: RKO) [7]
Etoposide + RTB101 DC1DBFW RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + RTB101 DCBTNQ3 RTB101 Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + SCH-900776 DC2ACXA SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [7]
Etoposide + SCH-900776 DCV1S66 SCH-900776 Breast carcinoma (Cell Line: KPL1) [7]
Etoposide + SCH-900776 DCTCQSY SCH-900776 Carcinoma (Cell Line: OV90) [7]
Etoposide + SCH-900776 DCYRD3S SCH-900776 Carcinoma (Cell Line: EFM192B) [7]
Etoposide + SCH-900776 DC0K7YD SCH-900776 Colon adenocarcinoma (Cell Line: LOVO) [7]
Etoposide + SCH-900776 DC6GKKK SCH-900776 Colon carcinoma (Cell Line: RKO) [7]
Etoposide + SCH-900776 DCU7WG2 SCH-900776 Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + SNX-2112 DCH03P7 SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [7]
Etoposide + SNX-2112 DCW7QH7 SNX-2112 Breast carcinoma (Cell Line: ZR751) [7]
Etoposide + SNX-2112 DCIB7PR SNX-2112 Carcinoma (Cell Line: OV90) [7]
Etoposide + SNX-2112 DC3EVRX SNX-2112 Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + SNX-2112 DC0Q9PA SNX-2112 Colon carcinoma (Cell Line: RKO) [7]
Etoposide + SNX-2112 DCDERPE SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + SNX-2112 DCVDVQR SNX-2112 Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + SCH 727965 DCXJFJL SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [7]
Etoposide + SCH 727965 DCT7JX6 SCH 727965 Breast carcinoma (Cell Line: KPL1) [7]
Etoposide + SCH 727965 DC0BLPN SCH 727965 Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + Erlotinib DC6JUJF Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [7]
Etoposide + Erlotinib DCDGFJ8 Erlotinib Breast carcinoma (Cell Line: ZR751) [7]
Etoposide + Erlotinib DC7UWCB Erlotinib Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + Erlotinib DC5O3FL Erlotinib Carcinoma (Cell Line: OV90) [7]
Etoposide + Erlotinib DCXQJMS Erlotinib Carcinoma (Cell Line: EFM192B) [7]
Etoposide + Erlotinib DC7U7VY Erlotinib Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + Erlotinib DCPIN8K Erlotinib Colon carcinoma (Cell Line: RKO) [7]
Etoposide + Erlotinib DCFOVH8 Erlotinib Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + Erlotinib DCVGNAZ Erlotinib Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + MK-5108 DC49G70 MK-5108 Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + MK-5108 DCSP5GN MK-5108 Carcinoma (Cell Line: OV90) [7]
Etoposide + MK-5108 DCIYN3G MK-5108 Carcinoma (Cell Line: EFM192B) [7]
Etoposide + MK-5108 DCOMNYX MK-5108 Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + MK-5108 DCY4I5V MK-5108 Colon carcinoma (Cell Line: RKO) [7]
Etoposide + Ridaforolimus DCHQFPY Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289) [7]
Etoposide + Ridaforolimus DCM531A Ridaforolimus Breast carcinoma (Cell Line: KPL1) [7]
Etoposide + Ridaforolimus DC58AVR Ridaforolimus Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + Ridaforolimus DCA806E Ridaforolimus Carcinoma (Cell Line: EFM192B) [7]
Etoposide + Ridaforolimus DC16211 Ridaforolimus Colon adenocarcinoma (Cell Line: LOVO) [7]
Etoposide + Ridaforolimus DCMOAP9 Ridaforolimus Colon carcinoma (Cell Line: RKO) [7]
Etoposide + Ridaforolimus DCKMPP2 Ridaforolimus Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + MK-4827 DC81M3J MK-4827 Breast carcinoma (Cell Line: KPL1) [7]
Etoposide + MK-4827 DCUIRW8 MK-4827 Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + MK-4827 DCMDRDC MK-4827 Carcinoma (Cell Line: EFM192B) [7]
Etoposide + MK-4827 DCAE54V MK-4827 Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + MK-4827 DCRW5SE MK-4827 Colon carcinoma (Cell Line: RKO) [7]
Etoposide + MK-4827 DCGWLCK MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + MK-4827 DCI4KM8 MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + Bortezomib DC2SMMZ Bortezomib Breast carcinoma (Cell Line: ZR751) [7]
Etoposide + Bortezomib DCWCPFX Bortezomib Colon adenocarcinoma (Cell Line: LOVO) [7]
Etoposide + Bortezomib DCLAO7B Bortezomib Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + GSK525762 DCDPMRZ GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [7]
Etoposide + GSK525762 DCAL2QA GSK525762 Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + Sorafenib DC3KZNM Sorafenib Breast carcinoma (Cell Line: ZR751) [7]
Etoposide + Sorafenib DC878Q7 Sorafenib Breast carcinoma (Cell Line: KPL1) [7]
Etoposide + Sorafenib DCNMBN0 Sorafenib Colon carcinoma (Cell Line: RKO) [7]
Etoposide + Sorafenib DCAR2NP Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + Sorafenib DCEB3Y0 Sorafenib Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + MK-2206 DCNIYJU MK-2206 Breast carcinoma (Cell Line: KPL1) [7]
Etoposide + MK-2206 DCLALNT MK-2206 Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + MK-2206 DCXU2X9 MK-2206 Carcinoma (Cell Line: OV90) [7]
Etoposide + MK-2206 DCL6W44 MK-2206 Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + MK-2206 DC53OD0 MK-2206 Colon carcinoma (Cell Line: RKO) [7]
Etoposide + MK-2206 DCDH1XN MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [7]
Etoposide + MK-2206 DCKSJVK MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [7]
Etoposide + Dasatinib DCMO17I Dasatinib Breast carcinoma (Cell Line: KPL1) [7]
Etoposide + Dasatinib DC7G497 Dasatinib Breast carcinoma (Cell Line: OCUBM) [7]
Etoposide + Dasatinib DC2JOG1 Dasatinib Carcinoma (Cell Line: MDAMB436) [7]
Etoposide + Dasatinib DCUDXNE Dasatinib Colon carcinoma (Cell Line: RKO) [7]
Etoposide + Dasatinib DCNV8U9 Dasatinib Rectal adenocarcinoma (Cell Line: SW837) [7]
Fluorouracil + Etoposide DCQ8BUA Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289) [7]
Fluorouracil + Etoposide DC0T007 Fluorouracil Breast carcinoma (Cell Line: KPL1) [7]
Fluorouracil + Etoposide DCAYR7Q Fluorouracil Breast carcinoma (Cell Line: OCUBM) [7]
Fluorouracil + Etoposide DC6S4TQ Fluorouracil Colon carcinoma (Cell Line: RKO) [7]
Fluorouracil + Etoposide DC3MQS4 Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [7]
Fluorouracil + Etoposide DCU6D6H Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [7]
Fluorouracil + Etoposide DCZ8NYZ Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [6]
Fluorouracil + Etoposide DCAF4PR Fluorouracil Adenocarcinoma (Cell Line: A427) [6]
Fluorouracil + Etoposide DCA6FWF Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [6]
Fluorouracil + Etoposide DCN3W7D Fluorouracil Adenocarcinoma (Cell Line: DLD1) [6]
Fluorouracil + Etoposide DCPSPHV Fluorouracil Adenocarcinoma (Cell Line: HCT116) [6]
Fluorouracil + Etoposide DCWJOGL Fluorouracil Adenocarcinoma (Cell Line: HT29) [6]
Fluorouracil + Etoposide DCZ2KI1 Fluorouracil Germ cell tumour (Cell Line: PA1) [6]
Fluorouracil + Etoposide DCB0IZO Fluorouracil Malignant melanoma (Cell Line: A375) [6]
Fluorouracil + Etoposide DCQ2ZZ3 Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [6]
Fluorouracil + Etoposide DCB3ZKZ Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [6]
Fluorouracil + Etoposide DCA13HV Fluorouracil Malignant melanoma (Cell Line: UACC62) [6]
Fluorouracil + Etoposide DCA0TTX Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
Fluorouracil + Etoposide DC2EV2B Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Fluorouracil + Etoposide DCZ4YOI Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [6]
JQ1 + Etoposide DCO2KAV JQ1 Ewing sarcoma (Cell Line: TC-71) [5]
LY2523355 + Etoposide DC0EYGM LY2523355 Ewing sarcoma (Cell Line: TC-71) [5]
Mitomycin + Etoposide DC2X4HV Mitomycin Ewing sarcoma (Cell Line: TC-71) [5]
Mitomycin + Etoposide DC4RP6V Mitomycin Hodgkin lymphoma (Cell Line: U-HO1) [6]
MK-1775 + Etoposide DCPNVCG MK-1775 Ewing sarcoma (Cell Line: TC-71) [5]
MK-1775 + Etoposide DCTV6RJ MK-1775 Hodgkin lymphoma (Cell Line: U-HO1) [5]
MK-2206 + Etoposide DC2ZE9D MK-2206 Ewing sarcoma (Cell Line: TC-71) [5]
MK-2206 + Etoposide DCJ5P2H MK-2206 Hodgkin lymphoma (Cell Line: U-HO1) [5]
OSI-906 + Etoposide DCZS8ES OSI-906 Ewing sarcoma (Cell Line: TC-71) [6]
Panobinostat + Etoposide DCV3UIR Panobinostat Ewing sarcoma (Cell Line: TC-71) [5]
PD-0325901 + Etoposide DC9AOIQ PD-0325901 Hodgkin lymphoma (Cell Line: U-HO1) [6]
PF-562271 + Etoposide DCYE105 PF-562271 Hodgkin lymphoma (Cell Line: U-HO1) [5]
THAPSIGARGIN + Etoposide DCBG6PS THAPSIGARGIN Ewing sarcoma (Cell Line: TC-71) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 453 DrugCom(s)
48 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
AC220 + Etoposide DCGLUFR AC220 Lymphoblastic Leukemia, Acute, Childhood [8]
Ciprofloxacin XR + Etoposide DCAO7UV Ciprofloxacin XR Leukemia [9]
Cyclophosphamide + Etoposide DCRAUA1 Cyclophosphamide Adult Acute Lymphoblastic Leukemia in Remission [10]
Cyclophosphamide + Etoposide DC9NZXL Cyclophosphamide Anaplastic Large Cell Lymphoma [11]
Cyclophosphamide + Etoposide DCWWWEK Cyclophosphamide Recurrent Adult Burkitt Lymphoma [12]
Cyclophosphamide + Etoposide DC3YMDJ Cyclophosphamide Adult Grade III Lymphomatoid Granulomatosis [13]
Cyclophosphamide + Etoposide DCC4UBO Cyclophosphamide Lymphoma [14]
Dexamethasone + Etoposide DCP9M07 Dexamethasone Hemophagocytic Syndrome [15]
Erlotinib + Etoposide DCBAO0J Erlotinib Recurrent Childhood Brain Tumor [16]
Etoposide + Temozolomide DC0F3Y4 Temozolomide Recurrent Childhood Brain Tumor [16]
Etoposide + Busulfan DC0OXFQ Busulfan Adult Acute Basophilic Leukemia [17]
Etoposide + Carboplatin DCIGYM6 Carboplatin Ewing's Family Tumors [18]
Etoposide + Nicotinamide DCSW9N4 Nicotinamide Hodgkin's Disease [19]
Etoposide + Carboplatin DC3JRQM Carboplatin Extensive Stage Small Cell Lung Cancer [20]
Etoposide + Cytarabine DC68MZD Cytarabine Adult Acute Basophilic Leukemia [17]
Etoposide + Oxaliplatin DC82FCV Oxaliplatin Angioimmunoblastic T-cell Lymphoma [21]
Etoposide + Zarnestra DCGQ0SQ Zarnestra Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome [22]
Etoposide + Zarnestra DCGWIHN Zarnestra Adult Acute Megakaryoblastic Leukemia (M7) [23]
Etoposide + Eflornithine DCJH6BL Eflornithine Neuroblastoma [24]
Etoposide + Busulfan DCPI550 Busulfan Adult Acute Myeloid Leukemia in Remission [25]
Etoposide + Vincristine DCZYELT Vincristine Brain Tumors [26]
Etoposide + Carboplatin DC0ZE2W Carboplatin Unspecified Adult Solid Tumor, Protocol Specific [27]
Etoposide + Vincristine DCMCVSB Vincristine Brain Tumors [28]
Etoposide + Vorinostat DCWKWJ0 Vorinostat Accelerated Phase Chronic Myelogenous Leukemia [29]
Everolimus + Etoposide DC6JCXF Everolimus Recurrent Childhood Brain Tumor [16]
Everolimus + Etoposide DCI4ZQF Everolimus Lung Cancer [30]
Ifosfamide + Etoposide DC44WIJ Ifosfamide Adult Nasal Type Extranodal NK/T-cell Lymphoma [31]
Ifosfamide + Etoposide DC5UYFN Ifosfamide Cancer [32]
Lenalidomide + Etoposide DCFWOZ6 Lenalidomide Adult Acute Megakaryoblastic Leukemia (M7) [33]
Plerixafor + Etoposide DC6K6C6 Plerixafor Adult Acute Lymphoblastic Leukemia in Remission [34]
Rubitecan + Etoposide DCJ7ALP Rubitecan Unspecified Adult Solid Tumor, Protocol Specific [35]
Cycloleucine + Etoposide DCL0ZQE Cycloleucine Extensive Stage Small Cell Lung Cancer [36]
Cycloleucine + Etoposide DCPSSFJ Cycloleucine Extensive Stage Small Cell Lung Cancer [36]
Cyclophosphamide + Etoposide DCIIRP0 Cyclophosphamide AIDS-related Diffuse Large Cell Lymphoma [37]
Cyclophosphamide + Etoposide DCU9D5P Cyclophosphamide Lymphoma [38]
Cyclophosphamide + Etoposide DCCX6PZ Cyclophosphamide Lymphoma [39]
Cyclophosphamide + Etoposide DCQG4P0 Cyclophosphamide Non-Hodgkin Lymphoma [40]
Etoposide + Melphalan DCSAF8Y Melphalan Lymphoma [41]
Etoposide + Idarubicin DCUIQMZ Idarubicin Leukemia [42]
Etoposide + Mitoxantrone DCXEHDI Mitoxantrone Adult Acute Megakaryoblastic Leukemia (M7) [43]
Etoposide + DTI-015 DC0MIZ8 DTI-015 Lymphoma [39]
Etoposide + Bortezomib DCM9986 Bortezomib Adult Acute Monoblastic Leukemia (M5a) [44]
Ifosfamide + Etoposide DCQUKV7 Ifosfamide Lymphoma [45]
Rivoceranib + Etoposide DCIAAGG Rivoceranib Non-small Cell Lung Cancer [46]
Cyclophosphamide + Etoposide DCSZO6I Cyclophosphamide Brain Cancer [47]
Etoposide + Daunorubicin DCO9Y73 Daunorubicin Acute Myeloid Leukemia [48]
Ifosfamide + Etoposide DCTFJPR Ifosfamide Recurrent Nasopharynx Carcinoma [49]
Dexamethasone + Etoposide DCBHK96 Dexamethasone Hemophagocytic Lymphohistiocytoses [50]
------------------------------------------------------------------------------------
⏷ Show the Full List of 48 DrugCom(s)

References

1 Etoposide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815).
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075635.
4 ClinicalTrials.gov (NCT04356690) Etoposide in Patients With COVID-19 Infection. U.S. National Institutes of Health.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
7 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
8 ClinicalTrials.gov (NCT01411267) AC220 for Children With Relapsed/Refractory ALL or AML
9 ClinicalTrials.gov (NCT02773732) Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
10 ClinicalTrials.gov (NCT00536601) High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
11 ClinicalTrials.gov (NCT00073918) Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
12 ClinicalTrials.gov (NCT00002649) Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
13 ClinicalTrials.gov (NCT01959477) Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
14 ClinicalTrials.gov (NCT00569985) Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
15 ClinicalTrials.gov (NCT05936086) A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
16 ClinicalTrials.gov (NCT02015728) Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
17 ClinicalTrials.gov (NCT00006363) Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
18 ClinicalTrials.gov (NCT01505569) Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
19 ClinicalTrials.gov (NCT00691210) Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
20 ClinicalTrials.gov (NCT00017251) Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
21 ClinicalTrials.gov (NCT00101205) Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
22 ClinicalTrials.gov (NCT00602771) Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
23 ClinicalTrials.gov (NCT00112853) Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
24 ClinicalTrials.gov (NCT01059071) Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
25 ClinicalTrials.gov (NCT00003875) Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia
26 ClinicalTrials.gov (NCT00003935) Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
27 ClinicalTrials.gov (NCT00027898) Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
28 ClinicalTrials.gov (NCT00003625) Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma
29 ClinicalTrials.gov (NCT00357305) Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
30 ClinicalTrials.gov (NCT00807755) Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
31 ClinicalTrials.gov (NCT00601718) Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
32 ClinicalTrials.gov (NCT00003597) Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
33 ClinicalTrials.gov (NCT01904643) Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
34 ClinicalTrials.gov (NCT01408043) Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
35 ClinicalTrials.gov (NCT00006047) Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
36 ClinicalTrials.gov (NCT00057837) Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
37 ClinicalTrials.gov (NCT01775475) Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
38 ClinicalTrials.gov (NCT00002941) Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
39 ClinicalTrials.gov (NCT00345865) Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
40 ClinicalTrials.gov (NCT03125642) Auto Stem Cell Transplant for Lymphoma Patients
41 ClinicalTrials.gov (NCT00695409) Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
42 ClinicalTrials.gov (NCT00534469) Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
43 ClinicalTrials.gov (NCT00634244) Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
44 ClinicalTrials.gov (NCT00666588) Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
45 ClinicalTrials.gov (NCT00006373) Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
46 ClinicalTrials.gov (NCT02733107) The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer
47 ClinicalTrials.gov (NCT01014767) Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
48 ClinicalTrials.gov (NCT00703820) Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
49 ClinicalTrials.gov (NCT02137096) Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
50 ClinicalTrials.gov (NCT05491304) Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis